Wedbush Expects Lower Earnings for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Wedbush dropped their Q2 2025 earnings per share estimates for Neurocrine Biosciences in a research report issued to clients and investors on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $1.00 for the quarter, down from their prior forecast of $1.12. Wedbush has a “Outperform” rating on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q3 2025 earnings at $1.30 EPS and FY2027 earnings at $8.97 EPS.

NBIX has been the topic of a number of other research reports. Needham & Company LLC lifted their target price on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th. HC Wainwright cut their target price on Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating on the stock in a research report on Tuesday, April 22nd. UBS Group raised their price target on Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a “buy” rating in a report on Wednesday, July 9th. BMO Capital Markets raised their price target on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a “market perform” rating in a report on Tuesday, May 6th. Finally, Piper Sandler reissued an “overweight” rating and set a $154.00 price target (down previously from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Stock Performance

NBIX opened at $134.11 on Thursday. The business’s 50-day simple moving average is $125.18 and its 200-day simple moving average is $121.53. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $157.98. The stock has a market capitalization of $13.27 billion, a P/E ratio of 45.46, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The firm had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. During the same quarter last year, the firm posted $1.20 EPS. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. OneDigital Investment Advisors LLC raised its position in shares of Neurocrine Biosciences by 2.1% during the 4th quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company’s stock worth $575,000 after purchasing an additional 87 shares during the last quarter. HighPoint Advisor Group LLC raised its position in shares of Neurocrine Biosciences by 4.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company’s stock worth $334,000 after purchasing an additional 96 shares during the last quarter. Huntington National Bank raised its position in shares of Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after purchasing an additional 97 shares during the last quarter. Utah Retirement Systems raised its position in shares of Neurocrine Biosciences by 0.6% during the 4th quarter. Utah Retirement Systems now owns 16,583 shares of the company’s stock worth $2,264,000 after purchasing an additional 100 shares during the last quarter. Finally, DE Burlo Group Inc. raised its position in shares of Neurocrine Biosciences by 2.2% during the 1st quarter. DE Burlo Group Inc. now owns 4,717 shares of the company’s stock worth $522,000 after purchasing an additional 100 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 9,613 shares of the business’s stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the sale, the director owned 514,596 shares of the company’s stock, valued at $61,947,066.48. The trade was a 1.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jude Onyia sold 59,819 shares of the business’s stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total value of $7,803,986.74. Following the sale, the insider directly owned 18,289 shares in the company, valued at $2,385,982.94. This trade represents a 76.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold 120,251 shares of company stock worth $14,978,602 over the last quarter. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.